Use of a reduced (4-dose) vaccine schedule for postexposure prophylaxis to prevent human rabies: recommendations of the Advisory Committee on Immunization Practices by United States Advisory Committee on Immunization Practices.
Please note: An erratum has been published for this issue. To view the erratum, please click here.
Morbidity and Mortality Weekly Report
www.cdc.gov/mmwr
Recommendations and Reports March 19, 2010 /  Vol. 59 /  No. RR-2
U s e  o f  a  R e d u c e d  ( 4 - D o s e )  V a c c i n e  
S c h e d u l e  f o r  P o s t e x p o s u r e  P r o p h y l a x i s  
t o  P r e v e n t  H u m a n  R a b i e s
Recomm endations of the A d visory  Committee 
on Immunization Practices
d e p a r t m e n t  o f  h e a l t h  a n d  h u m a n  s e r v i c e s  
c e n t e r s  f o r  D i s e a s e  C o n t r o l  a n d  P r e v e n t io n
MMWR
The MMWR series of publications is published by Surveillance, 
Epidemiology, and Laboratory Services, Centers for Disease Control 
and Prevention (CDC), U.S. Department of Health and Human 
Services, Atlanta, GA 30333.
Suggested Citation: Centers for Disease Control and Prevention. 
[Title]. MMWR 2010;59(No. RR-#):[inclusive page numbers].
Centers for Disease Control and Prevention
Thomas R. Frieden, MD, MPH 
Director 
Peter A. Briss, MD, MPH 
Acting Associate Director for Science 
James W. Stephens, PhD 
Office of the Associate Director for Science 
Stephen B. Thacker, MD, MSc 
Deputy Director for 
Surveillance, Epidemiology, and Laboratory Services
Editorial and Production Staff
Frederic E. Shaw, MD, JD 
Editor, MMWR Series 
Christine G. Casey, MD 
Deputy Editor, MMWR Series 
Teresa F. Rutledge 
Managing Editor, MMWR Series 
David C. Johnson 
Lead Technical Writer-Editor 
Jeffrey D. Sokolow, MA 
Project Editor 
Martha F. Boyd 
Lead Visual Information Specialist 
Malbea A. LaPete 
Stephen R. Spriggs 
Terraye M. Starr 
Visual Information Specialists 
Kim L. Bright 
Quang M. Doan, MBA 
Phyllis H. King 
Information Technology Specialists
____________ Editorial Board____________
William L. Roper, MD, MPH, Chapel Hill, NC, Chairman 
Virginia A. Caine, MD, Indianapolis, IN 
Jonathan E. Fielding, MD, MPH, MBA, Los Angeles, CA 
David W. Fleming, MD, Seattle, WA 
William E. Halperin, MD, DrPH, MPH, Newark, NJ 
King K. Holmes, MD, PhD, Seattle, WA 
Deborah Holtzman, PhD, Atlanta, GA 
John K. Iglehart, Bethesda, MD 
Dennis G. Maki, MD, Madison, WI 
Sue Mallonee, MPH, Oklahoma City, OK 
Patricia Quinlisk, MD, MPH, Des Moines, IA 
Patrick L. Remington, MD, MPH, Madison, WI 
Barbara K. Rimer, DrPH, Chapel Hill, NC 
John V. Rullan, MD, MPH, San Juan, PR 
William Schaffner, MD, Nashville, TN 
Anne Schuchat, MD, Atlanta, GA 
Dixie E. Snider, MD, MPH, Atlanta, GA 
John W. Ward, MD, Atlanta, GA
contents
I n t r o d u c t i o n ......................................................................................................................................................................................................... 1
M e t h o d s ......................................................................................................................................................................................................................2
R a t i o n a l e  f o r  R e d u c e d  D o s e s  o f  H u m a n  R a b i e s  V a c c i n e ........................................2
R e v i s e d  R a b i e s  P o s t e x p o s u r e  P r o p h y l a x i s  R e c o m m e n d a t i o n s ..................... 5
V a c c i n a t i o n  a n d  S e r o l o g i c  T e s t i n g ........................................................................................................................ 7
M a n a g e m e n t  o f  A d v e r s e  R e a c t i o n s ,  P r e c a u t i o n s ,
a n d  C o n t r a i n d i c a t i o n s ............................................................................................................................................................... 7
V a r i a t i o n  f r o m  H u m a n  R a b i e s  V a c c i n e  P a c k a g e  I n s e r t s ..........................................7
R e f e r e n c e s ..............................................................................................................................................................................................................8
Vol. 59 /  RR-2 Recommendations and Reports 1
Use of a Reduced (4-Dose) Vaccine Schedule for Postexposure  
Prophylaxis to Prevent Hum an Rabies
R e c o m m e n d a t i o n s  o f  t h e  A d v i s o r y  C o m m i t t e e  o n  I m m u n i z a t i o n  P r a c t i c e s
Prepared by 
Charles E. Rupprecht, VMD, PhD1 
Deborah Briggs, PhD2 
Catherine M. Brown, DVM3 
Richard Franka, DVM, PhD1 
Samuel L. Katz, MD4 
Harry D Kerr, MD5 
Susan M. Lett, MD3 
Robin Levis, PhD6 
Martin I. Meltzer, PhD1 
William Schaffner, MD7 
Paul R.Cieslak, MD8 
National Center for Emerging and Zoonotic Infectious Diseases (proposed), CDC 
2Kansas State University, Manhattan, Kansas 
3Massachusetts Department of Public Health, Jamaica Plain, Massachusetts 
4Duke University Medical Center, Durham, North Carolina
5.American College of Emergency Physicians, Dallas, Texas 
6Food and Drug Administration, Washington, District of Columbia 
7Vanderbilt University School of Medicine, Nashville, Tennessee 
8Oregon Department of Public Health, Corvallis, Oregon
S u m m a r y
This report summarizes new recommendation and updates previous recommendations o f the Advisory Committee on Immunization 
Practices (ACIP) for postexposure prophylaxis (PEP) to prevent human rabies (CDC. Human rabies prevention— United States, 
2008: recommendations o f the Advisory Committee on Immunization Practices. M M W R 2008;57[No. RR-3]). Previously, ACIP 
recommended a 5-dose rabies vaccination regimen with human diploid cell vaccine (HDCV) or purified chick embryo cell vaccine 
(PCECV). These new recommendations reduce the number o f vaccine doses to four. The reduction in doses recommended for PEP 
was based in part on evidence from rabies virus pathogenesis data, experimental animal work, clinical studies, and epidemiologic 
surveillance. These studies indicated that 4  vaccine doses in combination with rabies immune globulin (RIG) elicited adequate 
immune responses and that a fifth dose o f vaccine did not contribute to more favorable outcomes. For persons previously unvac­
cinated with rabies vaccine, the reduced regimen o f 4  1-mL doses o f H D CV or PCECV should be administered intramuscularly. 
The first dose o f the 4-dose course should be administered as soon as possible after exposure (day 0). Additional doses then should 
be administered on days 3, 7, and 14 after the first vaccination. ACIP recommendations for the use o f RIG remain unchanged. 
For persons who previously received a complete vaccination series (pre- or postexposure prophylaxis) with a cell-culture vaccine or 
who previously had a documented adequate rabies virus-neutralizing antibody titer following vaccination with noncell-culture 
vaccine, the recommendation for a 2-dose PEP vaccination series has not changed. Similarly, the number o f doses recommended 
for persons with altered immunocompetence has not changed; for such persons, PEP should continue to comprise a 5-dose vaccina­
tion regimen with 1 dose o f RIG. Recommendations for pre-exposure prophylaxis also remain unchanged, with 3 doses o f vaccine 
administered on days 0, 7, and 21 or 28. Prompt rabies PEP combining wound care, infiltration o f RIG into and around the 
wound, and multiple doses o f rabies cell-culture vaccine continue to be highly effective in preventing human rabies.
The material in this report originated in the National Center for 
Emerging and Zoonotic Infectious Diseases (proposed), Lonnie King, 
DVM, Director.
Corresponding preparer: Charles E. Rupprecht, VMD, PhD, National 
Center for Emerging and Zoonotic Infectious Diseases (proposed), 
1600 Clifton Road, N.E., MS G-33, Atlanta, GA 30333. Telephone: 
404-639-1050; Fax: 404-639-1564; E-mail: cyr5@cdc.gov.
I n t r o d u c t i o n
Rabies is a zoonotic disease caused by RNA viruses in the 
family Rhabdoviridae, genus Lyssavirus (1). Virus is transmitted 
in the saliva o f rabid mammals via a bite. After entry to the 
central nervous system, these viruses cause an acute, progres­
sive encephalomyelitis. The incubation period usually ranges 
from 1 to 3 months after exposure, but can range from days to
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years. Rabies can be prevented by avoidance of viral exposure 
and initiation of prom pt medical intervention when exposure 
does occur. In the United States, animal rabies is common. In 
a recent study, approximately 23,000 persons per year were 
estimated to have been exposed to potentially rabid animals 
and received rabies postexposure prophylaxis (PEP) (2). W ith 
the elimination of canine rabies virus variants and enzootic 
transmission among dogs, hum an rabies is now rare in the 
United States, with an average of one or two cases occurring 
annually since 1960 (3).
Prompt wound care and the administration of rabies immune 
globulin (RIG) and vaccine are highly effective in prevent­
ing hum an rabies following exposure. A variety of empirical 
schedules and vaccine doses have been recommended over time, 
based in part on immunogenicity and clinical experience in 
areas of the world with enzootic canine or wildlife rabies (4). 
As more potent vaccines were developed, the number of vaccine 
doses recommended for PEP has decreased, and studies aimed 
at further revision and reduction of PEP schedules and doses in 
humans have been encouraged. By the latter half of the 20th 
century, a 4- to 6-dose, intramuscular regimen using human 
diploid cell vaccine (HDCV) or purified chick embryo cell vac­
cine (PCECV) was being recommended (5—8). In the United 
States, a 5-dose PEP vaccine regimen was adopted during the 
1980s (9—12). In 2007, when hum an rabies vaccine was in 
limited supply, an ad hoc National Rabies Working Group was 
formed to reassess the recommendations for rabies prevention 
and control in humans and other animals. In 2008, a smaller 
Advisory C om m ittee on Im m unization Practices (ACIP) 
Rabies Workgroup was formed to review rabies vaccine regimen 
options. This report provides updated ACIP recommendations 
regarding the use o f a 4-dose vaccination regimen, replacing 
the previously recommended 5-dose regimen, for rabies PEP 
in previously unvaccinated persons.
M e t h o d s
The ACIP Rabies Workgroup* was formed in October 2008 
to review 1) previous recommendations; 2) published and 
unpublished data from both national and global sources regard­
ing rabies PEP; and 3) the immunogenicity, effectiveness, and 
safety of a 4-dose PEP rabies vaccination regimen. The ACIP 
Rabies Workgroup used an evidence-based process for consid­
eration of a reduced vaccination regimen in human rabies PEP 
This approach consisted o f a review o f information available 
from basic and applied studies o f rabies prevention. Because 
rabies is almost always fatal among immunologically naive
* A list of the membership appears on page 9 of this report.
persons once clinical symptoms of rabies occur, randomized, 
placebo-controlled efficacy studies of vaccine in humans cannot 
be conducted. The ACIP Rabies Workgroup reviewed six areas: 
1) rabies virus pathogenesis, 2) experimental animal models, 
3) human immunogenicity studies, 4) prophylaxis effectiveness 
in humans, 5) documented failures of prophylaxis in humans, 
and 6) vaccine safety. Studies for review were identified by 
searching the PubMed database and other relevant references 
and by consulting subject-matter experts. W hen definitive 
research evidence was lacking, the recommendations incor­
porated the expert opinion of the ACIP Rabies Workgroup 
members. The ACIP Rabies Workgroup also sought advice 
and comment from representatives of the vaccine industry, 
the National Association of State Public Health Veterinarians, 
the Council of State and Territorial Epidemiologists, state and 
local public health officials, additional national stakeholder 
groups, and other national and international experts. The 
proposed revised recommendations and a draft statement from 
the ACIP Rabies Workgroup were presented to the full ACIP 
during February 2009. After review and comment by ACIP, 
a revised draft, recommending a reduced regimen of 4 1-mL 
doses of rabies vaccine for PEP in previously unvaccinated 
persons, was prepared for consideration. These recommenda­
tions were discussed and accepted by ACIP at the June 2009 
meeting (13).
R a t i o n a l e  f o r  R e d u c e d  D o s e s  
o f  H u m a n  R a b i e s  V a c c i n e
A detailed review of the evidence in support of a reduced, 
4-dose schedule for hum an PEP has been published (14). 
The totality of the evidence, obtained from the available peer- 
reviewed literature, unpublished data sources, epidemiologic 
reviews, and expert opinion strongly supports a reduced vac­
cination schedule (Table 1). Since the 19 th century, prophy­
lactic interventions against rabies have recognized the highly 
neurotropic characteristics of lyssaviruses and have aimed at 
neutralizing the virus at the site of infection before it can enter 
the hum an central nervous system (Figure 1) (4,15,16). To 
accomplish this, immunologic interventions must be prompt 
and must be directed toward local virus neutralization, such as 
local infiltration with RIG and vaccination. M odern recom­
mended rabies PEP regimens emphasize early wound care and 
passive immunization (i.e., infiltration of RIG in and around 
the wound) combined with active immunization (i.e., serial 
doses of rabies vaccine). Accumulated scientific evidence indi­
cates that, following rabies virus exposure, successful neutral­
ization and clearance of rabies virus mediated via appropriate 
PEP generally ensures patient survival (8).
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TABLE 1. Summary of evidence in support of a 4-dose postexposure prophylaxis regimen — United States, 2010
Evidence C onclus ion Sources
Rabies virus 
pathogenesis
High neurotropism of rabies virus requires immediate immunization 
(local infiltration with human rabies immune globulin [HRIG] and 
vaccination) to neutralize virus at the site of infection and prevent viral 
entry into the central nervous system.
Published literature,* expert national and international 
opinion, and historic observations
Experimental animal 
models
Protection in animal models was elicited without regard to the 
absolute number of vaccine doses used.
Published literature^ expert national and international 
opinion, and unpublished data
Human clinical 
studies
All patients develop adequate levels of virus-neutralizing antibodies 
by day 14, without any additive value of a 5th dose of vaccine 
administered at day 28 (in regards to any substantive increase in 
measured virus-neutralizing antibody levels).
Published literature,® expert national and international 
opinion, and unpublished data
Epidemiologic
surveillance
No human rabies cases were identified in patients who received 
appropriate wound care, HRIG, and 4 doses of vaccine.
Published literature,^ expert national and international 
opinion, and unpublished data
Health economics Expected positive national benefits are related to omission of a 5th 
dose (e.g., minimized travel expenses, reduced time out of work, 
health-care workers have more time for other patients, and fewer 
adverse reactions).
Published literature** and expert national opinion
* SOURCES: Lyles DS, Rupprecht CE. Rhabdoviridae. In: Knipe D, Howley P, eds. Fields virology. 5th ed. Philadelphia, PA: Lippincott, Williams, & Wilkins; 
2007:1363-408. Plotkin SA, Koprowski H, Rupprecht CE. Rabies vaccines. In: Plotkin SA, Orenstein WA, Offit PA, eds. Vaccines. 5th ed. Philadelphia, PA: 
Saunders; 2008:687-714. World Health Organization. WHO Expert Consultation on Rabies. 1st report. WHO Technical Report Series, No. 931. Geneva, 
Switzerland: World Health Organization; 2005. Rupprecht CE, Briggs D, Brown C, et al. Evidence for a 4-dose vaccine schedule for human rabies post­
exposure prophylaxis in previously non-vaccinated individuals. Vaccine 2009;27:7141-8. Charlton KM, Nadin-Davis S, Casey GA, Wandeler AI. The long 
incubation period in rabies: delayed progression of infection in muscle at the site of exposure. Acta Neuropathol 1997;94:73-7. Dietzschold B, Schnell M, 
Koprowski H. Pathogenesis of rabies. Curr Top Microbiol Immunol 2005;292:45-56. 
t  SOURCES: Lyles DS, Rupprecht CE. Rhabdoviridae. In: Knipe D, Howley P, eds. Fields Virology. 5th Ed. Philadelphia, PA: Lippincott, Williams, & Wilkins; 
2007:1363-408. World Health Organization. WHO Expert Consultation on Rabies. 1st Report. WHO Technical Report Series, No. 931. Geneva, Switzer­
land: World Health Organization; 2005. Rupprecht CE, Briggs D, Brown C, et al. Evidence for a 4-dose vaccine schedule for human rabies post-exposure 
prophylaxis in previously non-vaccinated individuals. Vaccine 2009;27:7141-8. Baer GM. Animal models in the pathogenesis and treatment of rabies. 
Rev Infect Dis 1988;10(Suppl 4):S739-50. Franka R, Wu X, Jackson RF, et al. Rabies virus pathogenesis in relationship to intervention with inactivated 
and attenuated rabies vaccines. Vaccine 2009;27:7149-55. Sikes RK, Cleary WF, Koprowski H, Wiktor TJ, Kaplan MM. Effective protection of monkeys 
against death from street virus by post-exposure administration of tissue-culture rabies vaccine. Bull World Health Organ 1971;45:1-11. Manickama R, 
Basheer MD, Jayakumar R. Post-exposure prophylaxis (PEP) of rabies-infected Indian street dogs. Vaccine 2008;26:6564-8.
§ SOURCES: Plotkin SA, Koprowski H, Rupprecht CE. Rabies vaccines. In: Plotkin SA, Orenstein WA, Offit PA, eds. Vaccines. 5th ed. Philadelphia, PA: 
Saunders; 2008:687-714. World Health Organization. WHO Expert Consultation on Rabies. 1st Report. WHO Technical Report Series, No. 931. Geneva, 
Switzerland: World Health Organization; 2005. Rupprecht CE, Briggs D, Brown C, et al. Evidence for a 4-dose vaccine schedule for human rabies post­
exposure prophylaxis in previously non-vaccinated individuals. Vaccine 2009;27:7141-8.
H SOURCES: Plotkin SA, Koprowski H, Rupprecht CE. Rabies vaccines. In: Plotkin SA, Orenstein WA, Offit PA, eds. Vaccines. 5th ed. Philadelphia, PA: 
Saunders; 2008:687-714. Rupprecht CE, Briggs D, Brown C, et al. Evidence for a 4-dose vaccine schedule for human rabies post-exposure prophylaxis 
in previously non-vaccinated individuals. Vaccine 2009; 27:7141-8. Wilde H. Failures of post-exposure rabies prophylaxis. Vaccine 2007;25:7605-9.
** SOURCES: Meltzer MI, Rupprecht CE. A review of the economics of the prevention and control of rabies: I: global impact and rabies in humans. Phar- 
macoEconomics 1998:14:365-83. Dhankhar P, Vaidya SA, Fishbien DB, Meltzer MI. Cost effectiveness of rabies post exposure prophylaxis in the United 
States. Vaccine 2008;26:4251-5.
The induction of a rabies virus-specific antibody response is 
one important immunologic component of response to vac­
cination (4). Development o f detectable rabies virus-specific 
neutralizing antibodies is a surrogate for an adequate immune 
response to vaccination. Clinical trials of human rabies vaccina­
tion indicate that all healthy persons develop detectable rabies 
virus-neutralizing antibody titer rapidly after initiation of PET! 
For example, in a literature review conducted by the ACIP 
Rabies Workgroup of at least 12 published rabies vaccination 
studies during 1976-2008 representing approximately1,000 
human subjects, all subjects developed rabies virus-neutralizing 
antibodies by day 14 (14).
Observational studies indicate that PEP is universally effec­
tive in preventing hum an rabies when administered promptly 
and appropriately. O f the >55,000 persons who die annually of 
rabies worldwide, the majority either did not receive any PEP, 
received some form of PEP (usually without RIG) after sub­
stantial delays, or were administered PEP according to sched­
ules that deviated substantially from current ACIP or World 
Health Organization recommendations (17). For example, a 
review o f a series of 21 fatal hum an cases in which patients 
received some form of PEP indicated that 20 patients devel­
oped signs of illness, and most died before day 28 (Figure 2). 
In such cases, in which widespread infection of the central
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FIGURE 1. Schematic of dynamics of rabies virus pathogenesis* 
(PEP)-mediated immune responses*
in the presence and absence of postexposure prophylaxis
Days postexposure
* Rabies can progress through five stages: incubation period (5 days to >2 years: U.S. median ~35 days), prodrome state (0-10 days), acute neurologic 
period (2 -7  days), coma (5-14 days), and death.
t  Once in tissues at the entry site, rabies virus can be neutralized by passively administered rabies immune globulin (RIG). Active immunization (vaccine) 
stimulates the host immune system, and, as a result, virus-neutralizing antibodies (VNA) are produced approximately 7-10 days after initiation of vac­
cination. By approximately day 14-28 (after administration of 4 vaccine doses), VNAs peak. In the absence of early and adequate PEP, virus enters host 
neurons, spreads to the central nervous system (CNS), and causes disease, with inevitably fatal consequence.
§ Human rabies immune globulin.
H Day vaccine administered.
nervous system occurs before the due date (i.e., day 28) of the 
fifth vaccine dose, the utility of that dose must be nil. In the 
United States, of the 27 human rabies cases reported during 
2000—2008, none o f the patients had a history of receiving any 
PEP before illness, and this is the most common situation for 
hum an rabies deaths in both developed and developing coun­
tries (3,8). In India, an analysis from two animal bite centers 
during 2001—2002 demonstrated that in 192 human rabies 
cases, all deaths could be attributed to failure to seek timely 
and appropriate PEP, and none o f them could be attributed 
to a failure to receive the fifth (day 28) vaccine dose (18). 
Even when PEP is administered imperfectly or not according 
to established scheduled dose recommendations, it might be 
generally effective. Several studies have reported cases involving 
persons who were exposed to potentially rabid animals and who 
received less than 5, 4, or even 3 doses of rabies vaccine but
who nevertheless did not acquire rabies (Table 2). For example, 
in one series from New York, 147 (13%) o f 1,132 patients had 
no report of receiving the complete 5-dose vaccine regimen. O f 
these patients, 26 (18%) received only 4 doses o f vaccine, and 
two of these patients were exposed to animals with laboratory- 
confirmed rabies. However, no documented cases of human 
rabies occurred (CDC, unpublished data, 2003). The ACIP 
Rabies Working Group estimates that >1,000 persons in the 
United States receive rabies prophylaxis annually o f only 3 or 
4 doses, with no resulting documented cases of hum an rabies, 
even though >30% of these persons likely have exposure to 
confirmed rabid animals (14). In addition, no case of human 
rabies in the United States has been reported in which failure 
of PEP was attributable to receiving less than the 5-dose vac­
cine course. Worldwide, although hum an PEP failures have 
been reported very rarely, even in cases in which intervention
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FIGURE 2. Number of documented rabies postexposure pro­
phylaxis (PEP) failures — Burma, India, the Philippines, South 




I I Symptom onset 
I I Death
Before day 14 Days 14-28 
Days postexposure
After day 28
SO URC ES: W ilde H. Failures of post-exposure rabies prophylaxis. 
Vaccine 2007;25:7605-9; Wilde H, Sirikawin S, Sabcharoen A, et al. 
Failure of postexposure treatment of rabies in children. Clin Infect Dis 
1996;22:228-32; Matha IS, Salunke SR. Immunogenicity of purified vero 
cell rabies vaccine used in the treatment of fox-bite victims in India. Clin 
Infect Dis 2005;40:611-3.
* Of 21 reported PEP failures described, 20 patients had symptoms and 
15 died before day 28.
appeared both prompt and appropriate (8), no cases have been 
attributed to the lack of receipt o f the fifth hum an rabies vac­
cine dose on day 28 (4,17).
In vivo laboratory animal studies using multiple animal mod­
els from rodents to nonhum an primates have underscored the 
importance o f timely PEP using RIG and vaccine, regardless 
of the absolute number o f vaccine doses used or the schedule 
(14,19). For example, in a study in which 1, 2, 3, 4, or 5 
doses of rabies vaccine were used in a Syrian hamster model 
in combination with human rabies immune globulin (HRIG), 
no statistically significant differences in elicited protection and 
consequent survivorship were observed among groups receiving 
different doses (20). In the same study, using a murine model, 
no differences were detected in immunogenicity and efficacy 
of PEP with 2, 3, or 4 vaccine doses. In another study using a 
nonhum an primate model, 1 dose of cell-culture vaccine, in 
combination with RIG administered 6 hours postexposure, 
provided substantial protection (21). In another study, a 3-dose
regime was evaluated in a canine model and determined to be 
effective in preventing rabies (22).
Compared with older, nerve tissue-based products, adverse 
reactions associated with modern human rabies vaccination are 
uncommon (4). A review by the Workgroup o f published and 
unpublished human rabies vaccine clinical trials and Vaccine 
Adverse Event Reporting System data identified no adverse 
events that were correlated to a failure to receive the fifth vac­
cine dose. As some adverse reactions might be independent 
clinical events with each vaccine administration, the omission 
of the vaccine dose on day 28 might have some positive health 
benefits. Otherwise, the overall safety o f hum an rabies PEP is 
expected to be unchanged from the evidence provided in the 
2008 ACIP report (12).
Preliminary economic assessments support the cost savings 
associated with a reduced schedule of vaccination (23,24). The 
ACIP Rabies Workgroup has estimated that, assuming 100% 
compliance with a recommended vaccine regimen, a change in 
recommendation from a 5-dose schedule to a 4-dose schedule 
would save approximately $16.6 million in costs to the U.S. 
health-care system. Persons who receive rabies vaccination might 
see some savings related to deletion of the fifth recommended 
dose of vaccine, measured in both the cost of the vaccine and 
the costs associated with the additional medical visit.
R e v i s e d  R a b i e s  P o s t e x p o s u r e  
P r o p h y l a x i s  R e c o m m e n d a t i o n s
This report presents revised recommendations for human 
rabies PEP (Table 3). Rabies PEP includes wound care and 
administration o f both RIG and vaccine.
P o s t e x p o s u r e  P r o p h y la x i s  
f o r  U n v a c c in a te d  P e r s o n s
For unvaccinated persons, the combination o f RIG and 
vaccine is recommended for both bite and nonbite exposures, 
regardless of the time interval between exposure and initiation
TABLE 2. Number and percentage of patients with suspected rabies exposures who received <5 doses of vaccine — India, 2003; 
New York, 1998-2000; and Puerto Rico, 2008*
Loca tion  (year)
No. o f persons 
exposed
Persons w ho  rece ived <5 doses o f vacc ine  
No. (%)
No. o f docum ented 
rab ies deaths
New York (1998-2000)t 1,132 147 (13) 0
India (2003)§ 439 261 (59) 0
Puerto Rico (2008)H 191 30 (16) 0
* No cases of human rabies were recorded that were attributable to receipt of only 4 doses of vaccine. 
t  SOURCE: CDC, unpublished data, 2003.
§ SOURCE: Association for the Prevention and Control of Rabies (APCRI) in India. Assessing the burden of rabies in India: WHO sponsored national multi- 
centric rabies survey 2003. Final report May 2004. Available at http://rabies.org.in. Accessed March 8, 2010. Sudarshan MK, Madhusudana SN, Mahendra 
BJ, et al. Assessing the burden of human rabies in India: results of a national multi-center epidemiological survey. Intl J Infect Dis 2007;11:29-35.
H SOURCE: CDC, unpublished data, 2008.
0
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TABLE 3. Rabies postexposure prophylaxis (PEP) schedule — United States, 2010
V acc ina tion  sta tus In te rven tion Regim en*
Not previously vaccinated Wound cleansing All PEP should begin with immediate thorough cleansing of all wounds with soap and water. If 




Administer 20 IU/kg body weight. If anatomically feasible, the full dose should be infiltrated around 
and into the wound(s), and any remaining volume should be administered at an anatomical site 
(intramuscular [IM]) distant from vaccine administration. Also, HRIG should not be administered in 
the same syringe as vaccine. Because RIG might partially suppress active production of rabies virus 
antibody, no more than the recommended dose should be administered.
Vaccine Human diploid cell vaccine (HDCV) or purified chick embryo cell vaccine (PCECV) 1.0 mL, IM 
(deltoid areat ), 1 each on days 0,§ 3, 7 and 14.H
Previously vaccinated** Wound cleansing All PEP should begin with immediate thorough cleansing of all wounds with soap and water. If 
available, a virucidal agent such as povidine-iodine solution should be used to irrigate the wounds.
HRIG HRIG should not be administered.
Vaccine HDCV or PCECV 1.0 mL, IM (deltoid areat ), 1 each on days 0§ and 3.
* These regimens are applicable for persons in all age groups, including children.
t  The deltoid area is the only acceptable site of vaccination for adults and older children. For younger children, the outer aspect of the thigh may be used.
Vaccine should never be administered in the gluteal area.
§ Day 0 is the day dose 1 of vaccine is administered.
H For persons with immunosuppression, rabies PEP should be administered using all 5 doses of vaccine on days 0, 3, 7, 14, and 28.
** Any person with a history of pre-exposure vaccination with HDCV, PCECV, or rabies vaccine adsorbed (RVA); prior PEP with HDCV, PCECV or RVA; or 
previous vaccination with any other type of rabies vaccine and a documented history of antibody response to the prior vaccination.
of PEP. If  PEP has been initiated and appropriate laboratory 
diagnostic testing (i.e., the direct fluorescent antibody test) 
indicates that the animal that caused the exposure was not 
rabid, PEP may be discontinued.
Vaccine Use
A regimen of 4 1-mL vaccine doses of H D C V  or PCECV 
should be administered intramuscularly to previously unvac­
cinated persons (Table 3). The first dose o f the 4-dose regimen 
should be administered as soon as possible after exposure. 
The date of the first dose is considered to be day 0 o f the PEP 
series. Additional doses then should be administered on days 
3, 7, and 14 after the first vaccination. Recommendations for 
the site of the intramuscular vaccination remain unchanged 
(e.g., for adults, the deltoid area; for children, the anterolateral 
aspect of the thigh also is acceptable). The gluteal area should 
not be used because administration of vaccine in this area 
might result in a diminished immunologic response. Children 
should receive the same vaccine dose (i.e., vaccine volume) as 
recommended for adults.
HRIG Use
The recommendations for use o f immune globulin in rabies 
prophylaxis remain unchanged by the revised recommendation 
of a reduced rabies vaccine schedule. HRIG is administered 
once to previously unvaccinated persons to provide rabies virus- 
neutralizing antibody coverage until the patient responds to
vaccination by actively producing virus-neutralizing antibodies. 
HRIG is administered once on day 0 at the time PEP is initi­
ated, in conjunction with hum an rabies vaccines available for 
use in the United States. If HRIG was not administered when 
vaccination was begun on day 0, it can be administered up to 
and including day 7 of the PEP series (12,25). If  anatomically 
feasible, the full dose of HRIG is infiltrated around and into 
any wounds. Any remaining volume is injected intramuscu­
larly at a site distant from vaccine administration. HRIG is 
not administered in the same syringe or at the same anatomic 
site as the first vaccine dose. However, subsequent doses (i.e., 
on days 3, 7, and 14) of vaccine in the 4-dose vaccine series 
can be administered in the same anatomic location in which 
HRIG was administered.
P o s t e x p o s u r e  P r o p h y la x i s  
f o r  P r e v io u s ly  V a c c in a te d  P e r s o n s
Recommendations for PEP have not changed for persons 
who were vaccinated previously. Previously vaccinated persons 
are those who have received one of the ACIP-recommended 
pre- or postexposure prophylaxis regimens (with cell-culture 
vaccines) or those who received another vaccine regimen (or 
vaccines other than cell-culture vaccine) and had a docu­
mented adequate rabies virus-neutralizing antibody response. 
Previously vaccinated persons, as defined above, should receive 
2 vaccine doses (1.0 mL each in the deltoid), the first dose
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immediately and the second dose 3 days later. Administration 
of HRIG is unnecessary, and HRIG should not be administered 
to previously vaccinated persons to avoid possible inhibition 
of the relative strength or rapidity of an expected anamnestic 
response (26). Local wound care remains an important part of 
rabies PEP for any previously vaccinated persons.
V a c c i n a t i o n  a n d  S e r o l o g i c  T e s t in g  
P o s tv a c c in a t io n  S e r o lo g ic  t e s t i n g
All healthy persons tested in accordance with ACIP guide­
lines after completion o f at least a 4-dose regimen of rabies 
PEP should demonstrate an adequate antibody response against 
rabies virus (14). Therefore, no routine testing o f healthy 
patients completing PEP is necessary to document serocon­
version (12). W hen titers are obtained, serum specimens col­
lected 1—2 weeks after prophylaxis (after last dose of vaccine) 
should completely neutralize challenge virus at least at a 1:5 
serum dilution by the rapid fluorescent focus inhibition test 
(RFFIT). The rabies virus-neutralizing antibody titers will 
decline gradually since the last vaccination. Minimal differ­
ences (i.e., within one dilution of sera) in the reported values of 
rabies virus-neutralizing antibody results might occur between 
laboratories that provide antibody determination using the 
recommended RFFIT. Commercial rabies virus antibody titer 
determination kits that are not approved by the Food and Drug 
Administration are not appropriate for use as a substitute for 
the RFFIT. Discrepant results might occur after the use of such 
tests, and actual virus-neutralizing activity in clinical specimens 
cannot be measured.
M a n a g e m e n t  o f  A d v e r s e  
R e a c t i o n s ,  P r e c a u t i o n s ,  
a n d  C o n t r a i n d i c a t i o n s  
M a n a g e m e n t  o f  A d v e r s e  R e a c t io n s
Recommendations for management and reporting of vaccine 
adverse events have not changed. These recommendations have 
been described in detail previously (12).
I m m u n o s u p p r e s s io n
Recommendations for rabies pre- and postexposure pro­
phylaxis for persons w ith im m unosuppression have not 
changed. General recommendations for active and passive 
immunization in persons with altered immunocompetence 
have been summarized previously (27,28). This updated report
discusses specific recommendations for patients with altered 
immunocompetence who require rabies pre- and postexposure 
prophylaxis. All rabies vaccines licensed in the United States 
are inactivated cell-culture vaccines that can be administered 
safely to persons with altered immunocompetence. Because 
corticosteroids, other immunosuppressive agents, antimalari- 
als, and immunosuppressive illnesses might reduce immune 
responses to rabies vaccines substantially, for persons with 
immunosuppression, rabies PEP should be administered using 
a 5-dose vaccine regimen (i.e., 1 dose of vaccine on days 0, 3, 7, 
14, and 28), with the understanding that the immune response 
still might be inadequate. Immunosuppressive agents should 
not be administered during rabies PEP unless essential for the 
treatment of other conditions. If  possible, immunosuppressed 
patients should postpone rabies preexposure prophylaxis until 
the immunocompromising condition is resolved. W hen post­
ponement is not possible, immunosuppressed persons who are 
at risk for rabies should have their virus-neutralizing antibody 
responses checked after completing the preexposure series. 
Postvaccination rabies virus-neutralizing antibody values might 
be less than adequate among immunosuppressed persons with 
H IV  or other infections (29,30). W hen rabies pre- or postex­
posure prophylaxis is administered to an immunosuppressed 
person, one or more serum samples should be tested for rabies 
virus-neutralizing antibody by the RFFIT to ensure that an 
acceptable antibody response has developed after completing 
the series. If no acceptable antibody response is detected after 
the final dose in the pre- or postexposure prophylaxis series, the 
patient should be managed in consultation with their physician 
and appropriate public health officials.
V a r i a t i o n  f r o m  H u m a n  R a b i e s  
V a c c i n e  P a c k a g e  I n s e r t s
These new ACIP recommendations differ from current rabies 
vaccine label instructions, which still list the 5-dose series for 
PEP. Historically, ACIP review and subsequent public health 
recommendations for the use of various biologics has occurred 
after vaccine licensure and generally are in agreement with 
product labels. However, differences between ACIP recom­
mendations and product labels are not unprecedented. For 
example, during the early 1980s, ACIP review and recom­
mendations concerning the intradermal use of rabies vaccines 
occurred well in advance of actual label claims and licensing 
(9). O n the basis o f discussions with industry representatives, 
alterations o f current product labels for H D C V  and PCEC 
are not anticipated by the producers of hum an rabies vaccines 
licensed for use in the United States.
Please note: An erratum has been published for this issue. To view the erratum, please click here.
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